Arcutis Biotherapeutics Inc (NAS:ARQT)
$ 10.25 -0.59 (-5.44%) Market Cap: 1.20 Bil Enterprise Value: 1.15 Bil PE Ratio: 0 PB Ratio: 7.65 GF Score: 29/100

Q4 2022 Arcutis Biotherapeutics Inc Earnings Call Transcript

Feb 28, 2023 / 09:30PM GMT
Release Date Price: $16.18 (+1.25%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to Arcutis Biotherapeutics, Inc. Fourth Quarter 2022 Earnings Conference Call. (Operator Instructions) Please note that today's conference is being recorded.

I will now hand the conference over to your speaker host, Eric McIntyre, Head of Investor Relations. Please go ahead.

Eric McIntyre
Arcutis Biotherapeutics, Inc. - Head of IR

Thank you, Olivia. Good afternoon, everyone, and thank you for joining Arcutis' Fourth Quarter and Full Year 2022 Earnings Call. Slides are available on the Investors section of our website.

On today's call, we have Frank Watanabe, President and CEO; Scott Burrows, Chief Financial Officer; Ken Lock, Chief Commercial Officer; and Patrick Burnett, Chief Medical Officer. During this call, I'd remind everyone that we will be making forward-looking statements. These statements are subject to certain risks and uncertainties and our actual results may differ materially. We encourage you to review the information disclosed in our latest SEC filings.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot